Centro Universitario de Ciencias de la Salud, Mexico

2 marketed · 3 in Phase 3

Quick facts

Marketed products

green tea extract · Oncology, Cardiovascular, Metabolic, General wellness
Green tea extract contains polyphenols, primarily catechins and EGCG, which act as antioxidants and anti-inflammatory agents to reduce oxidative stress and cellular damage.
Losartan and Amlodipine · Cardiovascular
Losartan blocks angiotensin II receptors to reduce vasoconstriction and aldosterone release, while amlodipine blocks calcium channels to relax blood vessels, together lowering blood pressure.

Phase 3 pipeline

Calcined magnesia · Gastroenterology
Calcined magnesia (magnesium oxide) acts as an antacid and laxative by neutralizing gastric acid and promoting bowel motility.
Dapagliflozin Pill · Diabetes
Dapagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.
Empagliflozin Pill · Diabetes
Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and lower blood glucose levels.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Centro Universitario de Ciencias de la Salud, Mexico

What are Centro Universitario de Ciencias de la Salud, Mexico's marketed drugs?

Top marketed products include green tea extract, Losartan and Amlodipine.

What is Centro Universitario de Ciencias de la Salud, Mexico's pipeline?

Centro Universitario de Ciencias de la Salud, Mexico has 3 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Calcined magnesia, Dapagliflozin Pill, Empagliflozin Pill.

green tea extract · Oncology, Cardiovascular, Metabolic, General wellness
Losartan and Amlodipine · Cardiovascular
Sector hub: All tracked pharma companies